Ironwood Pharmaceuticals INC

Ironwood Pharmaceuticals' stockholders approved an amendment to its 2019 Equity Incentive Plan, increasing the share pool by 10 million shares.

Ironwood Pharmaceuticals announced the resignation of its CFO, Gregory Martini, effective May 15, 2026, with Ronald Silver appointed as interim CFO.

Ironwood Pharmaceuticals announced robust first quarter 2026 financial results, driven by a significant 97% year-over-year increase in LINZESS U.S. net sales, while maintaining full-year financial guidance.

Ironwood Pharmaceuticals reported strong fourth quarter and full-year 2025 results, surpassing financial guidance and reiterating an optimistic 2026 outlook driven by LINZESS and apraglutide.

Ironwood Pharmaceuticals announced robust financial guidance for full-year 2026, projecting significant increases in LINZESS U.S. net sales, total revenue, and adjusted EBITDA, while maintaining its 2025 guidance.

Ironwood Pharmaceuticals' subsidiary, VectivBio, has settled a patent dispute with Ferring International Center S.A. and amended their exclusive license agreement, involving a $12.5 million payment and revised royalty structure.

Ironwood Pharmaceuticals reported a significant increase in net income for Q3 2025, driven by higher LINZESS sales and reduced operating expenses, despite a required confirmatory Phase III trial for apraglutide and ongoing restructuring.

Ironwood Pharmaceuticals reports a significant quarterly net income turnaround driven by cost reductions, despite a revenue decline and an FDA requirement for a confirmatory Phase III trial for apraglutide.

Ironwood Pharmaceuticals' Q1 2025 revenue decreased due to lower LINZESS sales, prompting a strategic review while the company advances its pipeline.

Ironwood Pharmaceuticals reported a net income of $3.6 million for the third quarter of 2024, a decrease compared to the $14 million net income in the same period last year, while also highlighting progress in its clinical pipeline.

Ironwood Pharmaceuticals reported a net loss for Q2 2024, impacted by decreased LINZESS revenue, while highlighting progress with its apraglutide program.

Ironwood Pharmaceuticals reported a net loss for the first quarter of 2024, primarily due to a decrease in LINZESS revenue, despite advancements in their apraglutide program.

Ironwood Pharmaceuticals reports a decrease in 2025 collaborative revenue for LINZESS due to pricing and inventory shifts, while advancing its apraglutide program despite a required confirmatory Phase III trial.

Ironwood Pharmaceuticals' 2024 results show a decrease in LINZESS revenue but progress in its pipeline, particularly with apraglutide.

Ironwood Pharmaceuticals' 2023 10-K filing highlights the company's focus on maximizing LINZESS, advancing its GI pipeline, and delivering sustained profits and cash flow, including the acquisition of VectivBio and progress on apraglutide.

Jeffrey Silber, SVP, CMO, Head-Res&Drug of Ironwood Pharmaceuticals Inc, received 137,036 shares of common stock on July 20, 2026.

Ronald Silver, an officer at Ironwood Pharmaceuticals, reported a sale of 127,890 shares of Class A Common Stock on July 7, 2026, executed under a Rule 10b5-1 trading plan.

Ironwood Pharmaceuticals Director Jay Shepard reported a transaction involving Class A Common Stock on June 16, 2026.

Marla L. Kessler, a Director at Ironwood Pharmaceuticals Inc., received a grant of 63,481 shares of Class A Common Stock on June 16, 2026.

Mark G. Currie, a Director at Ironwood Pharmaceuticals Inc., received a grant of 63,481 shares of Class A Common Stock on June 16, 2026.

Duane R. Jon, a Director at Ironwood Pharmaceuticals Inc., received a grant of 63,481 shares of Class A Common Stock on June 16, 2026.

Ironwood Pharmaceuticals, Inc. has issued its proxy statement detailing the agenda for its 2026 Annual Meeting of Stockholders, including director elections, executive compensation votes, and equity plan amendments.

Ironwood Pharmaceuticals has scheduled its 2025 Annual Meeting for June 10, 2025, outlining key proposals for stockholder voting, including the election of directors and executive compensation.

Ironwood Pharmaceuticals will hold its 2025 annual meeting of stockholders virtually on June 10, 2025, to vote on director elections, executive compensation, and auditor ratification.

Ironwood Pharmaceuticals has scheduled its annual stockholder meeting for June 18, 2024, where stockholders will vote on the election of directors, executive compensation, and the ratification of the company's independent auditor.

Ironwood Pharmaceuticals' proxy statement details the agenda for the 2024 annual meeting of stockholders and highlights the company's progress in maximizing LINZESS, advancing its GI pipeline, and delivering sustained profits and cash flows.

Sarissa Capital Management LP and Alexander J. Denner have reduced their beneficial ownership in Ironwood Pharmaceuticals Inc. to 5.6% and 5.8% respectively, following significant share sales.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 15,028,000 shares, representing 9.22% of Ironwood Pharmaceuticals, Inc.'s Class A common stock as of March 31, 2026.

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have filed a Schedule 13G, reporting beneficial ownership of 4.90% of Ironwood Pharmaceuticals Inc.'s Class A common stock as of March 31, 2026.

Bank of America Corporation has reported a beneficial ownership of 6.1% in Ironwood Pharmaceuticals Inc. as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Ironwood Pharmaceuticals Inc. following an internal realignment.

Bank of America Corporation has disclosed a 7.4% beneficial ownership stake in Ironwood Pharmaceuticals Inc.'s Class A Common Stock.

Barclays PLC has reported a 1.95% beneficial ownership stake in Ironwood Pharmaceuticals Inc., holding 3,167,713 common shares.